peptide YY

(redirected from PYY 3-36)

peptide YY

pep·tide YY

(pep'tīd)
A hormone released by the small intestine to signal the brain to stop eating.

peptide YY

An appetite-regulating protein released by L cells of the mucosa of the gastrointestinal tract in response to a meal. It binds to cells in the arcuate nucleus of the brain, decreases the desire to eat, and creates a feeling of fullness.
See also: peptide
References in periodicals archive ?
Company Strengthens PYY 3-36 Patent Estate for Treatment of Obesity and Makes Equity Investment in Thiakis Limited
Bothell, WA) announced it has acquired exclusive worldwide rights to the Cedars-Sinai Medical Center (Los Angeles, CA) (CSMC) Peptide YY patent, patent applications, and proprietary know-how estate to support ongoing commercialization efforts of Nastech's investigational PYY 3-36 Nasal Spray for Obesity.
Leptin * PYY 3-36 * Leptin with PYY 3-36 * Approved oral anti-obesity agents
Bothell, WA) announced today it has acquired exclusive worldwide rights to the Cedars-Sinai Medical Center (Los Angeles, CA) (CSMC) Peptide YY patent , patent applications, and proprietary know-how estate to support ongoing commercialization efforts of Nastech's investigational PYY 3-36 Nasal Spray for Obesity.
Our alliance with Merck for worldwide development and commercialization of PYY 3-36 for obesity was important both financially and strategically as it marked the first alliance involving one of our peptide delivery programs.
announced today it has acquired exclusive worldwide rights to the Cedars-Sinai Medical Center, Los Angeles, CA (CSMC) Peptide YY patent, patent applications, and proprietary know-how estate to support ongoing commercialization efforts of Nastech's investigational PYY 3-36 Nasal Spray for Obesity.
Independent researchers have reported acute reductions in food intake in humans using PYY 3-36.
a leader in drug delivery technology, today reported positive results from a Phase I-B study with PYY 3-36 (PYY) nasal spray for obesity and positive results from a Phase II Maximum Tolerated Dose (MTD) study with apomorphine nasal spray for sexual dysfunction.
today announced the completion and interim results for a Phase I dose-ranging study demonstrating the successful nasal delivery of PYY 3-36 (PYY) for treatment of obesity.
a leader in drug delivery technology, today announced the presentation of data on the development of its nasal spray formulation of PYY 3-36 (PYY) at the 2003 Annual Meeting of the North American Association for the Study of Obesity being held in Ft.
Results were successful in demonstrating "proof-of-concept" that the eligen(TM) technology could orally deliver the PYY 3-36 peptide in an in vivo model.